WuXi Biologics and NBE-Therapeutics announce a complete collaboration for the development and production of ADC
Thursday, April 11, 2019
WuXi Biologics, a global leading open access technology platform for biological products that offers comprehensive solutions for the discovery, development and production of biological products; and NBE-Therapeutics (NBE), a Swiss private equity biotechnology company that develops the best next-generation pharmacological antibody conjugates (ADCs), have announced a full collaboration for the development and production of NBE's first ADC product, NBE-002 (antiROR1).NBE-002 is the best immunostimulatory ADC treatment (iADC) to fight cancer with ROR1 and is scheduled to go into the clinical trial phase by mid 2020 in patients with triple negative breast cancer and other indications.
NBE-Therapeutics develops next-generation iADC products with the aim of improving the outcome of oncology patients, as it continues to develop iADC with its exclusive technology platforms. With its exclusive SMAC-Technology TM technologyto generate specific ADC conjugates per center and its exclusive platform of high-potency anthracite toxins, NBE has the ability to develop highly specialized treatments with long-term antitumor immunity. The collaboration with WuXi Biologics will allow the NBE product to be offered for clinical trials in investigational new drug applications (IND) around the world. With the creation of a solution center for integrated and cutting-edge biological products, WuXi Biologics provides a comprehensive and comprehensive service to global partners in terms of antibodies, ADC drugs and other drugs.
Dr. Ulf Grawunder , CEO of NBE-Therapeutics commented: "We are very excited about our collaboration with WuXi Biologics, who we consider one of the world's leading CDMOs in the manufacture of biological treatments." WuXi Biologics will be a partner solid in our next step in the development of our promising cancer treatments with anti - tumor immunity long term. This collaboration will accelerate the transition of our development programs preclinical IADC for clinical validation . We look forward to start working with WuXi Biologics in the next years to offer improved treatment options to cancer patients around the world. "
"We are pleased that NBE-Therapeutics, which has one of the best ADC platforms in the industry, has selected WuXi Biologics as a long-term partner for its promising ADR antiROR1 program, another sign of superior quality and global excellence. of our integrated services, which continue to drive the rapid expansion of our market share in Europe.We are excited to work with seven companies in more than 10 programs in Switzerland alone, "commented Dr. Chris Chen, CEO of WuXi Biologics. "Through our global quality, our first-class technical capabilities and unprecedented capabilities, we aim to empower global partners to discover, develop and manufacture biological products that benefit patients around the world."
